- Home
- AKRO vs LUMN Comparison
AKRO vs LUMN Comparison
Compare AKRO & LUMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- LUMN
- Stock Information
- Founded
- AKRO 2017
- LUMN 1968
- Country
- AKRO United States
- LUMN United States
- Employees
- AKRO N/A
- LUMN N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- LUMN Telecommunications Equipment
- Sector
- AKRO Health Care
- LUMN Telecommunications
- Exchange
- AKRO Nasdaq
- LUMN Nasdaq
- Market Cap
- AKRO 3.9B
- LUMN 4.1B
- IPO Year
- AKRO 2019
- LUMN 1972
- Fundamental
- Price
- AKRO $54.20
- LUMN $3.95
- Analyst Decision
- AKRO Strong Buy
- LUMN Hold
- Analyst Count
- AKRO 6
- LUMN 9
- Target Price
- AKRO $82.50
- LUMN $4.78
- AVG Volume (30 Days)
- AKRO 1.8M
- LUMN 11.3M
- Earning Date
- AKRO 08-08-2025
- LUMN 08-05-2025
- Dividend Yield
- AKRO N/A
- LUMN N/A
- EPS Growth
- AKRO N/A
- LUMN N/A
- EPS
- AKRO N/A
- LUMN N/A
- Revenue
- AKRO N/A
- LUMN $13,000,000,000.00
- Revenue This Year
- AKRO N/A
- LUMN N/A
- Revenue Next Year
- AKRO N/A
- LUMN N/A
- P/E Ratio
- AKRO N/A
- LUMN N/A
- Revenue Growth
- AKRO N/A
- LUMN N/A
- 52 Week Low
- AKRO $21.02
- LUMN $0.97
- 52 Week High
- AKRO $58.40
- LUMN $10.33
- Technical
- Relative Strength Index (RSI)
- AKRO 62.96
- LUMN 47.59
- Support Level
- AKRO $53.61
- LUMN $3.98
- Resistance Level
- AKRO $56.49
- LUMN $4.26
- Average True Range (ATR)
- AKRO 2.40
- LUMN 0.22
- MACD
- AKRO -0.08
- LUMN -0.02
- Stochastic Oscillator
- AKRO 65.93
- LUMN 29.03
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About LUMN Lumen Technologies Inc.
With 450,000 route miles of fiber, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 in 2017 and divestiture of much of its incumbent local exchange carrier, or ILEC, business in 2022 have shifted the company's operations away from its legacy consumer business and toward enterprises (now about 75% of revenue). Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen has announced the sale of its consumer fiber network, but will maintain and harvest its legacy consumer copper network.